CalciMedica (NASDAQ:CALC) Posts Earnings Results

CalciMedica (NASDAQ:CALC) issued its quarterly earnings results on Tuesday. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06, Zacks reports.

CalciMedica Stock Up 2.2%

Shares of CalciMedica stock traded up $0.01 during trading on Tuesday, hitting $0.60. The stock had a trading volume of 45,095 shares, compared to its average volume of 902,756. The company has a market capitalization of $9.51 million, a PE ratio of -0.31 and a beta of 0.85. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The stock has a 50 day simple moving average of $0.63 and a 200 day simple moving average of $2.57.

Wall Street Analysts Forecast Growth

CALC has been the topic of several recent analyst reports. Oppenheimer dropped their target price on CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. Wall Street Zen upgraded CalciMedica to a “sell” rating in a report on Saturday, January 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $13.00.

Institutional Trading of CalciMedica

A number of hedge funds have recently modified their holdings of CALC. Envestnet Asset Management Inc. lifted its holdings in shares of CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of CalciMedica by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of CalciMedica in the fourth quarter valued at $127,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of CalciMedica in the fourth quarter valued at $506,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.